Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	211.95	269.57	519.27	1,323	286.93	291.14
Short-Term Investments	7.3	7.3	148.42	16.12	-	-
Cash & Short-Term Investments	219.25	276.87	667.69	1,339	286.93	291.14
Cash Growth	-54.23%	-58.53%	-50.15%	366.84%	-1.45%	5.02%
Accounts Receivable	128.46	140.74	58.53	81.32	320.84	169.03
Other Receivables	6.47	7.73	4.69	3.09	11.33	5.51
Receivables	134.93	148.47	63.22	84.41	332.17	174.54
Inventory	93.75	64.94	112.33	246.72	173.3	84.85
Prepaid Expenses	69.4	71.45	83.25	103.22	89.28	23.82
Other Current Assets	188.74	174.66	171.53	149.95	15.73	2.16
Total Current Assets	706.05	736.38	1,098	1,924	897.41	576.51
Property, Plant & Equipment	1,615	1,705	1,847	1,978	1,351	786.73
Long-Term Investments	162.13	177.87	190.81	199.51	109.59	191.81
Goodwill	23.92	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	8.98	12.34	18.98	25.93	33.71	36.72
Long-Term Deferred Tax Assets	102.93	98.6	95.49	89.72	81.11	83.45
Other Long-Term Assets	595.84	614.67	495.85	211.93	642.46	53.41
Total Assets	3,215	3,368	3,770	4,453	3,139	1,753
Accounts Payable	56.44	34.63	44.05	52.52	54.68	40.31
Accrued Expenses	66.92	98.05	112.32	104.21	96.4	66.6
Short-Term Debt	150	-	-	100	50	100
Current Portion of Long-Term Debt	196.55	168.08	125.92	105.88	15.6	-
Current Portion of Leases	27.99	31.92	30.57	37.28	28.59	24.33
Current Income Taxes Payable	-	-	-	-	-	0.65
Current Unearned Revenue	300.76	230.85	187.28	142.28	152.12	125.9
Other Current Liabilities	42.84	97.97	253.28	92.57	142.69	66.99
Total Current Liabilities	841.51	661.5	753.42	634.73	540.07	424.78
Long-Term Debt	531.95	611.37	530.4	656.32	474.4	-
Long-Term Leases	74.6	72.04	39.39	56.37	176.06	72.28
Long-Term Deferred Tax Liabilities	-	-	-	-	3.75	6.68
Other Long-Term Liabilities	0.05	-	-	-	38.07	37.14
Total Liabilities	1,448	1,345	1,323	1,347	1,232	540.89
Common Stock	2,071	2,070	2,059	2,053	1,533	1,282
Additional Paid-In Capital	58.04	421.11	1,074	1,468	576.95	53.11
Retained Earnings	-362.1	-466.91	-682.64	-406.83	-254.34	-207.23
Comprehensive Income & Other	-0.26	-0.79	-3.32	-8.8	50.72	83.41
Shareholders' Equity	1,767	2,023	2,447	3,106	1,907	1,212
Total Liabilities & Equity	3,215	3,368	3,770	4,453	3,139	1,753
Total Debt	981.09	883.39	726.28	955.85	744.64	196.61
Net Cash (Debt)	-761.85	-606.53	-58.59	383.63	-457.72	94.53
Net Cash Growth	-	-	-	-	-	-58.98%
Net Cash Per Share	-3.69	-2.94	-0.29	2.32	-3.08	0.73
Filing Date Shares Outstanding	207.11	207.01	205.89	205.31	153.33	128.24
Total Common Shares Outstanding	207.11	207.01	205.89	205.31	153.33	128.24
Working Capital	-135.45	74.89	344.59	1,289	357.34	151.73
Book Value Per Share	8.53	9.77	11.89	15.13	12.43	9.45
Tangible Book Value	1,734	1,987	2,404	3,056	1,849	1,151
Tangible Book Value Per Share	8.37	9.60	11.68	14.88	12.06	8.98
Buildings	792.86	792.86	792.86	791.68	-	-
Machinery	1,598	1,594	1,603	1,575	837.57	688.02
Construction In Progress	185.34	158.09	106.85	3.35	624.35	260.37
Leasehold Improvements	325.53	325.53	317.34	307.77	276.23	246.21

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.